Comprehensive Augmented Reality Testing (CART) Platform for Parkinson’s disease

帕金森病综合增强现实测试 (CART) 平台

• 批准号: 10688198
• 负责人: JAY L. ALBERTS
• 金额: $ 63.01万
• 依托单位: CLEVELAND CLINIC LERNER COM-CWRU
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-09-01 至 2027-07-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10688198
• 关键词: 3-Dimensional; Activities of Daily Living; Advisory Committees; Age; Alzheimer' s Disease; Area; Attention; Augmented Reality; Biological Markers; Biomechanics; Biomedical Engineering; Bradykinesia; Caring; Clinical; Clinical assessments; Cohort Studies; Collaborations; Coupled; Data; Deep Brain Stimulation; Development; Devices; Disease; Disease Progression; Electronics; Engineering; Ensure; Environment; Exhibits; Fingers; Functional disorder; Future; Gait; Goals; Human; Image; Independent Living; Individual; Individual Differences; Letters; Life; Link; Measurement; Measures; Medical; Military Personnel; Modeling; Monitor; Motion; Motor; Movement; Movement Disorder Society Unified Parkinson' s Disease Rating Scale; National Institute of Neurological Disorders and Stroke; Neurology; Neuropsychology; Outcome; Outcome Measure; Parkinson Disease; Patients; Pattern; Performance; Pharmaceutical Preparations; Physical therapy; Psychometrics; Reality Testing; Series; Software Engineering; Soldier; Standardization; Symptoms; System; Task Performances; Technology; Testing; Time; Tremor; Validation; Validity and Reliability; clinical care; clinical decision-making; clinical diagnosis; cognitive function; cognitive task; cohort; computer generated; digital; digital imaging; effective therapy; experimental study; falls; food preparation; innovation; instrumental activity of daily living; mild traumatic brain injury; multidisciplinary; nervous system disorder; neurosurgery; novel; patient oriented; population based; sensor; software development; statistics; success; symposium; symptom treatment; technology platform; treatment strategy

PROJECT SUMMARY/ABSTRACT Parkinson’s disease (PD) is the fastest growing neurological disease, outpacing even Alzheimer’s. A gap in the effective treatment of PD is the reliance on capacity-based clinical assessments, such as the MDS-UPDRS III, to guide clinical decision-making. Clinical ratings, while simple to administer, provide a poor estimation of PD performance of instrumental activities of daily living (IADLs). Declines in IADL performance are of particular importance, as recent population-based cohort studies indicate that IADL decline pre-dates clinical diagnosis of PD by 5-7 years and predict the transition from independence to dependent care settings. In order to advance PD treatment and discovery, objective measures of disease symptoms during the performance of ‘real-world’ IADL scenarios must be created. Augmented reality technology, in which computer-generated images are superimposed in the user’s real-world view, enable the presentation of digital scenarios to replicate IADLs and objectively quantify user’s performance via integrated IMUs and depth camera. The primary aim of this project is to develop an accurate, valid, and reliable augmented reality assessment platform for the quantification of motor and non-motor performance of PD under clinical and IADL augmented reality environments. The proposed Comprehensive Augmented Reality Test (CART) platform for PD will objectively quantify the cardinal motor signs of PD, as well as IADL performance, to facilitate comprehensive treatment of symptoms and precise tracking of disease progression that can eventually be used to optimize medication and deep brain stimulation programming. A multi-disciplinary team of experts in the areas of software and biomedical engineering, neurology, neurosurgery, neuropsychology, physical therapy and statistics will collaborate to develop the CART platform and determine its accuracy, validity and reliability. Particular attention will be spent on quantifying the interplay between motor and cognitive tasks, as dual-tasks performance is linked to gait dysfunction and falls and historically has been overlooked in clinical assessments. Following the development stage, a series of psychometric studies and analyses will be conducted to determine the accuracy, validity and reliability of the CART platform in a cohort of 140 individuals with PD (n=35 in each Hoehn and Yahr Stage I- IV) and 35 age-matched controls. The CART PD platform has the potential to transform the treatment of PD globally by creating an equal emphasis on clinical symptoms and IADL performance through the use of an affordable consumer-available electronic device that is suitable for the integration into treatment delivery systems.

项目摘要/摘要 帕金森病（PD）是增长最快的神经系统疾病，甚至超过了阿尔茨海默氏症。中的间隙 PD的有效治疗依赖于基于能力的临床评估，例如MDS-CRISPR III， 来指导临床决策。临床评级虽然易于管理，但对PD的估计较差 工具性日常生活活动（IADL）。IADL表现的下降尤其 重要性，因为最近基于人群的队列研究表明，IADL下降早于临床诊断， PD 5-7年，并预测从独立到依赖护理环境的过渡。为了推进 PD治疗和发现，客观衡量疾病症状的过程中表现的“真实世界” 必须创建IADL场景。增强现实技术，其中计算机生成的图像是 叠加在用户的真实世界视图中，使数字场景的呈现能够复制IADL， 通过集成的伊穆斯和深度相机客观地量化用户的表现。这个项目的主要目的是 开发一个准确、有效、可靠的增强现实评估平台， 临床和IADL增强现实环境下PD的运动和非运动表现。的 提出的PD综合增强现实测试（CART）平台将客观地量化基数 PD的运动体征以及IADL表现，以促进症状的综合治疗， 精确跟踪疾病进展，最终可用于优化药物治疗和脑深部 刺激程序软件和生物医学领域的多学科专家团队 工程、神经病学、神经外科、神经心理学、物理治疗和统计学将合作， 开发CART平台并确定其准确性、有效性和可靠性。将特别注意 量化运动和认知任务之间的相互作用，因为双重任务的表现与步态有关 功能障碍和福尔斯，历史上在临床评估中被忽视。随着发展 在此阶段，将进行一系列的心理测量研究和分析，以确定准确性，有效性和 CART平台在140例PD患者队列中的可靠性（Hoehn和Yahr I期各35例） IV）和35个年龄匹配的对照组。CART PD平台有可能改变PD的治疗 在全球范围内，通过使用 适合整合到治疗输送中的经济实惠的消费者可用电子设备 系统.